BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » manufacturing » Page 3

GenCure Opens BioManufacturing Center for cGMP Production of Human MSCs

January 10, 2018 By Cade Hildreth (CEO) Leave a Comment

Biologics development and manufacturing organization supports transfer of laboratory research from preclinical evaluation through clinical trials and commercialization

San Antonio, Texas, Jan. 10, 2018 — GenCure today opened the first phase of a new biomanufacturing center designed to address a critical roadblock slowing the advancement of cellular therapies and the field of regenerative medicine: A lack of access to large-scale stem cell manufacturing and support services required for cGMP (Current Good Manufacturing Process)-compliant production of biologics for use in human clinical trials and commercial manufacturing.

“The new GenCure BioManufacturing Center is one of only a handful of independent manufacturing facilities in the U.S. for human bone marrow-derived mesenchymal stromal cells (hMSCs), the most widely used type of stem cell in both research and clinical settings,” said GenCure Chief Operating Officer Becky Cap. [Read more…]

Filed Under: Stem Cells Tagged With: GenCure, manufacturing

WuXi Biologics Initiated cGMP Manufacturing in the World’s Largest Biologics Manufacturing Facility Using Only Single-Use Bioreactors

December 6, 2017 By Cade Hildreth (CEO) Leave a Comment

WuXi Biologics, Chinese Manufacturing Plant

December 6, 2017, WUXI, China, Dec. 6, 2017  — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, announced that its cGMP biologics manufacturing facility in Wuxi city with 30,000 L bioreactor capacity entered into full operations. This marks a significant milestone for WuXi Biologics as well as the biologics industry in China.

[Read more…]

Filed Under: Cell Therapy Tagged With: manufacturing, WuXi

Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts

October 30, 2017 By Cade Hildreth (CEO) Leave a Comment

Facility located in the UMass Medicine Science Park will support clinical development and commercialization of CAR T pipeline

Preparations underway for clinical production in 2018

NEW YORK, Oct. 30, 2017 — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech, Inc. (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced today that it has entered into a lease agreement with the UMass Medicine Science Park in Worcester, Massachusetts, for a manufacturing facility to support the clinical development and commercialization of the Company’s CAR T product candidates.

Mustang Bio - CAR-T ManufacturingThe facility is expected to be operational for the production of personalized CAR T therapies in 2018. Mustang anticipates initially building cell-processing capabilities to support its lead CAR T product candidates MB-101 in glioblastoma, and MB-102 in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. [Read more…]

Filed Under: Cell Therapy, Press Releases Tagged With: CAR-T, manufacturing

Academic and Medical CDMOs Serving the Cell Therapy Industry

July 28, 2017 By Cade Hildreth (CEO) Leave a Comment

Academic and Medical Center CDMOs

In addition to commercial cell therapy CDMOs, there are other industry players that support the cell therapy industry, including academic and medical CDMOs. While these groups do contribute to the cell therapy CDMO market, their manufacturing capabilities are limited in scale and best suited to small, early-stage clinical trials. [Read more…]

Filed Under: Stem Cells Tagged With: cell therapy, manufacturing

Evolution of the Cell Therapy CDMO Market

July 26, 2017 By Cade Hildreth (CEO) Leave a Comment

Cell Therapy - CDMO Market

Traditionally, the contract development and manufacturing organization (CDMO) market was for pharmaceutical services, including drug compound development and manufacturing. Over time, many pharmaceutical companies expanded into offering services for biopharmaceuticals and biologics as well, and a companies went as far as to specialize in cell therapy CDMO services. [Read more…]

Filed Under: Stem Cells Tagged With: cell therapy, manufacturing

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.